

Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-cell Lymphomas

Nina Dusílková ^{1,2,†}, Petra Bašová ^{1,†}, Jindřich Polívka ³, Ondřej Kodet ^{1,4}, Vojtěch Kulvait ¹, Michal Pešta ⁵, Marek Trněný ³ and Tomáš Stopka ^{1,3,*}




Figure S1. Predicted probability of therapy response based on miR levels. Predicted probability that a patient has a particular therapy response (CR, PR, SD, PG) or belong to BL/healthy control. Upper 4 panels: Influence of miR-203 level (X axis) at certain levels of either miR-155 (0.5 vs 1.5) or miR-205 (0.5 vs 1.0). Lower 4 panels: Influence of miR-205 level (X axis) at certain levels of either miR-155 (0.5 vs 1.5) or miR-203 (0.1 vs 1.0).




Figure S2. Predicted probability of belonging to particular diagnosis or tumor size based on miR levels. **(A)** Predicted probability that a patient is healthy, benign or at 5 malignant stages (IA, IB, IIA, IIB, IIIA) based on the ordered logistic regression model. Increasing miR-155 (X axis) increase the probability of belonging to the progressed stage of CTCL seen at three levels of miR-203 (0.1, 0.5, 1.0). Bottom panel: accordingly, decreasing miR-203 (X axis) increase the probability of belonging to the progressed stage of CTCL seen at three levels of miR-155 (0.5, 1.0, 1.5); **(B)** Predicted probability that a patient is healthy, benign or at 4 malignant tumor stages (T1-T4) based on the ordered logistic regression model. Increasing miR-155 (X axis) increase the probability of belonging to the larger tumor size of CTCL seen at three levels of miR-203 (0.1, 0.5, 1.0). Bottom panel: accordingly, decreasing miR-203 (X axis) increase the probability of belonging to the larger tumor size of CTCL seen at three levels of miR-155 (0.5, 1.0, 1.5).